wire

Novartis drug Jakavi improved overall survival of myelofibrosis patients and impacted an underlying mechanism of disease
Jakavi reduced risk of death by 52% and sustained reductions in spleen size in new three-year COMFORT-II study data Analysis from a separate trial suggested that long-term treatment with Jakavi may stabilize or improve bone marrow fibrosis, a key marker of worsening disease Basel, June 16, 2013 - Novartis today announced results from a Phase III three-year follow-up study that showed Jakavi (ruxolitinib) demonstrated improved overall survival and sustained reductions in spleen size compared to conventional therapy.

Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis
Gilenya resulted in almost 50% more patients being free of MS disease activity after the switch from standard interferon treatment Annualized relapse rate reduced by >50% after 1 year for patients who switched from standard interferon treatment to Gilenya Reduced rate of brain volume loss sustained for up to 4.5 years in patients with active disease, despite prior treatment, who switched from interferon to Gilenya Basel, Ju

New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
Gilenya improved the key measures: brain volume loss, MRI lesion activity, relapse rates and disability progression Switching to Gilenya from interferon increased the proportion of patients disease free after one year of treatment Gilenya resulted in sustained reduction of annualized relapse rate and the rate of brain volume loss in patients switched from interferon treatment Basel, June 5 , 2013 - New data will

Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer
Investigational compound LDK378 is a selective inhibitor of ALK , a target found in metastatic non-small cell lung cancer (NSCLC) Data show 60% overall response rate in 78 patients with ALK+ NSCLC taking LDK378 at 750 mg; will serve as basis for first filing in early 2014 FDA designated LDK378 as Breakthrough Therapy in March and a robust clinical development plan is underway Basel, June 3 , 2013 - Novartis today anno

Novartis pivotal Phase III trial shows Afinitor significantly delays tumor growth in HER2 positive advanced breast cancer
A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients First Phase I

Lucentis receives positive opinion for patients with myopic choroidal neovascularization showing vision gains with only two injections
Lucentis recommended for approval in EU to treat patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Lucentis superior to current standard

Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
Latest Phase III research on Afinitor in HER2 positive advanced breast cancer Jakavi TM overall survival advantage evaluated in three-year study in patients with myelofibrosis,

World MS Day: Novartis launches a new campaign to raise awareness of MS and the unique experiences of people living with the disease
New campaign 'MS and:Our Story' announced today, providing MS community with platform to share experiences of life with MS Launch of new Novartis social media platforms to help gene

Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerability issues
INTERVAL study marks first assessment of the feasibility of setting and achieving individualized goals in this difficult-to-treat population of type 2 diabetes patients Study shows elderly type 2 diabetes patients three times more likely to reach an individualized HbA1c goal with no tolerability issues with vildagliptin than placebo Previous studies raised questions of uniform HbA1c targets for elderly type 2 diabetes patients,

New data from the Novartis chronic obstructive pulmonary disease (COPD) portfolio
New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations BLAZE study showed once-daily QVA149 significantly improved patient self-reported shortness of breath and lung function compared to placebo and tiotropium 18 mc g SPARK results showed that QVA149 significantly reduced rate of all exacerbations compared to glycopyrronium 50 mcg a

Women with advanced breast cancer feel left out of the breast cancer movement
Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement.

Novartis drug Afinitor significantly extended time without disease progression in women with HER2 positive advanced breast cancer
Everolimus plus trastuzumab and vinorelbine met primary endpoint of extending PFS compared to placebo plus trastuzumab and vinorelbine after prior therapy Results of Phase III trial, BOLERO-3,

Novartis drug Ilaris approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Ilaris (canakinumab) is the first interleukin-1 beta inhibitor for the treatment of SJIA and the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection

Real-world data at ARVO highlight transformational outcomes seen with Lucentis , including lower injection frequency than in original clinical trials
UK real world study shows 59% reduction of legal blindness attributable to wet AMD since introduction of Lucentis with 9.7 injections spread over 5 years New one year REPAIR data shows visual acuity improvement of 14 letters with an average of 3.6 Lucentis injections in myopic CNV patients Largest Lucentis meta-analysis, over 10,000 patients, confirms well-established safety profile reported from extensive clinical trials and

Novartis signs on to support Malaria No More’s Power of One campaign to stride towards a future without malaria
Power of One donation campaign harnesses the latest web and mobile technology to rally the global public to fight malaria Novartis will donate up to three million courses of pediatric antimalar

Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth
Sustained commitment to innovation resulted in eight key approvals in the EU and US and strong pipeline progress EMA approved Jetrea, Bexsero , a new indication for Ilaris and a line extensio

Novartis discloses compensation for new Chairman and Chairman ad-interim
Dr. Joerg Reinhardt to receive total annual compensation of CHF 3.8 million through combination of cash and stock for serving as Chairman of Novartis.

Novartis once-daily QVA149 shows superior efficacy in reducing exacerbations, improving lung function and quality of life in COPD patients
SPARK results published in Lancet Respiratory Medicine showed that dual bronchodilator QVA149 significantly reduced the rate of moderate or severe COPD exacerbations compared to glycopyrronium 50 mcg QVA149 significantly reduced the rate of all COPD exacerbations compared to open-label tiotropium 18 mcg and glycopyrronium Basel, April 23, 2013 - Results from the 64-week SPARK study published today in Lancet Respiratory Medicine showe

Alcon announces FDA approval of Simbrinza(TM) Suspension, a new beta blocker-free, fixed-combination therapy for glaucoma patients
Simbrinza offers a wide range of treatment possibilities due to its strong efficacy, providing sustained control and a 21%-35% reduction in intraocular pressure , , Combines Brinzolamide 1.

Supreme Court denial of Glivec patent clarifies limited intellectual property protection
Patent denied despite global recognition of Glivec as a life-saving, breakthrough drug for certain forms of cancer, with patents granted in nearly 40 countries Novartis has never been grant

Novartis confirms growing Gilenya clinical and real-world experience as number of patients treated increases to over 63,000
Growing global evidence base reinforces consistent and sustained efficacy of first once-daily oral multiple sclerosis treatment Gilenya is the only approved MS treatment shown to consistently decrease brain volume loss across studies with a significant effect seen as early as six months Low rate of brain volume loss with Gilenya sustained for up to four years in Phase III studies and for up to seven years in patients after complet

New analysis shows Novartis drug Gilenya significantly reduced rate of brain volume loss across three large Phase III studies
Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS Gilenya is the first oral disease modifying treatment to show consistent effect on brain volume loss, an important indicator of disease progression Analysis of FREEDOMS II, a Phase III study, confirms Gilenya consistently reduces annualized relapse rates across disease

Alcon announces EU approval of Jetrea , first and only eye drug to treat sight-threatening vitreomacular traction and macular hole
Jetrea represents a breakthrough for patients with vitreomacular traction (VMT), a sight-threatening progressive condition, if left untreated One-time intravitreal injection

Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer
LDK378 is an investigational selective inhibitor of ALK , a target found in a variety of cancers including metastatic non-small cell lung cancer (NSCLC) Breakthrough Therapy designation is based on positive early data in patients with ALK+ NSCLC who have been previously treated with crizotinib First filing for LDK378 anticipated in early 2014 Basel, March 15, 2013 - Novartis announced today that its investigational compoun

Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis
New data from three Phase III studies underlines efficacy and adds to growing global experience with Gilenya in more than 50,000 patients worldwide Data from over 500 patients treated for up to four years reinforces the known, manageable safety profile of once-daily oral Gilenya Progress reported with Novartis portfolio in studies of patients with primary-progressive MS and secondary-progressive MS, form

Novartis receives EU approval for Ilaris in patients suffering acute gouty arthritis attacks who cannot gain relief from current treatments
Ilaris is the first biologic approved in the EU for symptomatic pain relief in a gouty arthritis indication, and is administered in a single, subcutaneous injection The intense infl

Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa
RHD has been eliminated in most developed nations, but sub-Saharan Africa studies show at least 2-3% of school-age children suffer from this often fatal disease Collaboration between Novarti

Novartis reports Phase III data showing omalizumab improved itch in patients with a chronic form of hives who failed standard therapy[1]
Study published in NEJM today and presented tomorrow met primary endpoint in moderate to severe refractory chronic idiopathic/spontaneous urticaria (CIU/CSU) Up to two-thirds (66%) of omalizu

Shareholders approve all resolutions proposed by Novartis Board of Directors - Dr. Joerg Reinhardt to succeed as Chairman following transition period
Shareholders approve 16 th consecutive dividend increase to CHF 2.30 (+2%) per share for 2012, representing a payout of approximately 65% of net income from continuing operations New com

Novartis Board of Directors and Dr. Daniel Vasella agree to cancel the non-compete agreement and all related compensation; Decision taken to address concerns of stakeholders
Basel, 19 February 2013 - Novartis announced that the Novartis Board of Directors and Daniel Vasella have agreed to cancel his non-compete agreement with Novartis and all related conditional compensation.

Novartis drug Zortress is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation Approval based on

Novartis drug Exjade first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate Patients with NTDT accumulate excess iron increasing their risk of complications, including liver fibrosis, cirrhosis, blood clots, and bone and vascular disease At least three quarters of a million people worldwide have NTDT - and many patients are undiagnosed until seri

Novartis receives EU approval for Bexsero , first vaccine to prevent the leading cause of life-threatening meningitis across Europe
Bexsero is indicated to help protect all age groups against meningococcal serogroup B (MenB) disease, including infants who are the most vulnerable MenB disease is associated with a high human

Novartis receives positive CHMP opinion for Ilaris to treat patients whose acute gouty arthritis cannot be managed with standard of care
CHMP endorsed the use of Ilaris in patients with acute gouty arthritis, who suffer frequent attacks and for whom current treatments are unsuitable or ineffective Ilaris, the only approved ful

Jetrea(TM) receives positive CHMP opinion, would become the first drug to treat sight-threatening vitreomacular traction and macular hole
Pivotal data showed Jetrea significantly resolved vitreomacular traction (VMT) and macular hole compared to placebo at day 28 (p<0.001) Current standard of care for VMT is surgery or "watchf

Novartis makes progress in the fight to eliminate leprosy worldwide
Novartis advances goals set as part of a coordinated, international effort to eliminate or control 10 neglected tropical diseases (NTDs) Over 500 facilities in Tanzania now use SMS for Life

Pivotal study in The Lancet shows potential of Novartis vaccine Bexsero to help provide broad protection to infants against MenB
Phase III results show that Bexsero induced a robust immune response when administered concomitantly with routine vaccines, and also as a booster dose Data confirm Bexsero's acceptable safety and tolerability profile in infants, who are among the most vulnerable to MenB, a leading cause of meningitis Bexsero was recommended for European licensure in November 2012; upon approval, Bexsero will be the first and only broad cover

Phase III data in The Lancet show significant benefit of Novartis drug Afinitor in patients with non-cancerous tumors associated with TSC
More than 40% of TSC patients on everolimus had their kidney tumor volume reduced by at least half with no tumor progression Separate data show 35% of TSC patients treated with everolimus had their SEGA brain tumor volume reduced by one half or more Tuberous sclerosis complex (TSC), a genetic disorder, may cause non-cancerous tumors to form in vital organs, including the kidney and brain Basel, January 10, 2013

Novartis drug Exjade approved by European Commission
Novartis drug Exjade approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia Exjade is the first oral treatment approved in the EU for chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event